Ritlecitinib

(Litfulo®)

Litfulo®

Drug updated on 11/17/2023

Dosage FormCapsule (oral; 50 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults and adolescents (12 years and older) with severe alopecia areata

Product Monograph / Prescribing Information

Document TitleYearSource
Litfulo (ritlecitinib) Prescribing Information2023Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses